Mapi-Pharma postpones $18 million IPO

By Renaissance Capital,

Shutterstock photo

Mapi-Pharma, which is developing extended-release formulations of existing drugs and generics, postponed its IPO on Tuesday. The Ness Ziona, Israel-based company was founded in 2008 and planned to list on the NASDAQ under the symbol MAPI. Aegis Capital was set to be the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: MAPI

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by